July 2016: This guidance was re‑issued after a change to the commercial arrangements in July 2016. It was verified that this change did not impact cost effectiveness. Recommendation 1.1, sections 2.3 and 5.4, and the summary of appraisal committee key conclusions table have been updated.
January 2014: Implementation section updated to clarify that abiraterone is recommended as an option for treating castration‑resistant metastatic prostate cancer previously treated with a docetaxel‑containing regimen. Additional minor maintenance update also carried out.